Condition: Small Cell Lung Cancer Extensive Stage · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
This description comes directly from the study's public registry record.
Xian Zhong · 86-571-86993769 · zhongxian_2000@163.com
Always discuss trial participation with your own doctor first.
| Second Affiliated Hospital of Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06749691